Endogenous and Natural Complement Inhibitor Attenuates Myocardial Injury and Arterial Thrombogenesis

Abstract

Our results suggest that the natural, endogenous inhibitor MAP-1 effectively inhibits lectin pathway activation in vivo. MAP-1 at pharmacological doses represents a novel therapeutic approach for human diseases involving the lectin pathway and its associated MASPs.